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Abstract 
 
 Medical device registration for class three devices, such as a catheter ablator, can be a 
long and difficult process. The regulatory requirements can vary greatly by country, overlap and 
benefit one another, or require repeating a certification depending on the country in question. 
Determining the order in which to enter specific countries greatly depends on the size of the 
potential market and the costs and time needed for regulatory approval. Prior approval on major 
facets such as clinical trials may greatly reduce the costs of entering a particular country if the 
data from an outside source is deemed acceptable. This creates a complex problem where start-
ups who cannot afford to pursue regulatory approval in all major markets simultaneously must 
carefully chose and enter individual markets a few at a time. The paper will evaluate the 
regulatory pathways of ten select countries. This regulatory analysis, combined with a market 
analysis on these same countries by the other three members of the project, will form a basis 
from which we can create a suggested order of entry. 
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Background 
 
 Atrial Fibrillation (AF) is the most common form of arrhythmia, accounting for 
approximately 40% of all cases of arrhythmia. Arrhythmia is defined as an irregular heart rhythm 
caused by electrical imbalances in the heart. In atrial fibrillation, these irregularities are caused 
by electrical signals being issued too fast or randomly by the sinoatrial node, causing the heart to 
quiver rather than fully contract.  Atrial Fibrillation is more difficult to treat than other kinds of 
arrhythmias and there currently exists only three options for AF patients. First, the patient may 
opt for medications, which include antiarrhythmic or rate control drugs along with 
anticoagulants, such as warfarin, for the remainder of one’s life. Surgical ablation may be 
performed by a cardiac surgeon, operating outside the heart on the pericardium. Finally, there are 
catheter ablations which include the CircumBlator
TM
. Catheter ablations were first used in the 
late eighties and subsequent incremental improvements have done little to change the success 
rate of ablations. Current catheter ablation operations have a wildly varying success rate, 
between 50-80%, and are highly dependent on the skill of the electro-physiologist performing 
them. 
 AblaCor’s CircumBlatorTM claims to fix this problem by removing significant chance of 
surgeon error from the procedure. The CircumBlator
TM
 holds itself within the pulmonary vein 
using a stent-like device, called an anchor. The ablation is then performed using a 
circumferential radiofrequency ablator with an electrode array around the vein. This process 
improves upon existing methods by using the anchor to hold the ablator electrodes in place, 
which provides improved contact between the electrode and target tissue, freeing the surgeon of 
the task of ablating several individual points by hand. This reduces procedure time, making it 
more attractive economically, will reduce the number of images required and subsequent 
radiation exposure and improve the quality of the lesion created by the ablation. The result 
should be a simpler to perform operation, attracting more physicians to perform it and less 
reliance on highly skilled physicians to achieve a higher rate of success. 
 Accessing a particular market with a new medical device can be very costly. Novel 
devices must have substantial clinical data to demonstrate their safety and efficacy which is 
difficult to conduct under the budget of a startup medical company. The goal of this paper is to 
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minimize the cost of entry by finding the most cost-effective regulatory pathways to the largest 
individual markets. This will be done by comparing the approval processes, forms, fees, tests, 
and personnel needed to access a particular country. How likely a certain country is to accept 
international clinical data is a key factor in most major markets and certain countries may 
outright refuse approval unless clinical tests are conducted within their own boarders.  
 By understanding the requisite regulatory steps needed to sell a new medical device in a 
certain country, the cost-benefit of entering that particular country can then be determined based 
on the size of the market. This paper is meant to supplement a market review of the ten select 
countries initially chosen for analysis. As the regulatory steps are a cost to entering a certain 
country, fully determining the benefit of a given market relies on understanding numerous 
factors that surround the device. Markets are affected by AF arrhythmia demographics, wealth of 
a nation, number of surgeons capable of performing the operation, reimbursement policies, and 
many other factors. This paper will routinely use a nation’s wealth (defined by annual 
investments in medical devices by that nation) as a rough estimate of a given nation’s market 
size. A forthcoming full and detailed review of the markets will use this paper as a regulatory 
basis and combined they will outline our suggestions for the best order of entry. 
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Project Purpose 
 
 Understanding the regulatory process of a country is a critical component in determining 
the cost and benefit of entering a particular nation. Regulatory systems are complex; often 
impact one another, and approval runs the risk of becoming increasingly costly if the applicant is 
not prepared. The approval process in all countries must be able to show safety and efficacy of 
the device making the quality of clinical data the key factor. Most nations accept clinical data 
from studies conducted outside their boarders but will independently determine whether or not 
the data is considered sufficient for “statistically significant results” as defined by ISO 14155. As 
a result, it is important to conduct initial clinical trials in an area with high standards and a high 
reputation for quality. The three regulatory systems with the highest reputations and most widely 
accepted sources of clinical data are in the United States, European Union, and Japan. 
 Once the first location of clinical trials has been chosen, other regulatory processes may 
be considered as though they had sufficient clinical data (if outside data is accepted). Whether or 
not clinical data from the first trial location are accepted elsewhere will greatly impact the order 
of entry internationally. 
 Given this above information, determining the optimal order of entry becomes dependent 
on the knowledge of several diverse types of data. Understanding and organizing this 
information in such a way that it becomes clear which countries are worth pursuing requires a 
variety of skills taught in the Management major. With the knowledge gained through classes 
like Business Law and Achieving Strategic Effectiveness we can define regulatory pathways and 
estimate market sizes of a given country. This data can then be collected and evaluated using 
techniques found in data analysis and our knowledge of entrepreneurial startups and their 
limitations.   
9 | P a g e  
 
Methods 
 
European CE Marking Process 
 The European approval process is a decentralized and highly efficient regulatory 
approval route designed to give all member countries access to new medical technologies. CE 
Marking is not a mark of quality, the process of CE Marking is actually a “self-declaration” 
whereby the manufacturer claims to be in compliance with the guidelines necessary for free trade 
within the European Economic Area (EEA). The CE Mark effectively functions as a “pre-market 
approval”, which includes the lengthy technical documentation and collection of clinical data 
processes. This is the most expensive aspect of the approval process and afterward registering a 
device in an individual European nation is quick and economical. Europe, like most other nations 
uses a three tier device classification system based on complexity of the device and the risk 
associated with it. Class I devices are simple tools such as elastic bandages, sterile gloves, or 
medical grade scalpels. Class II devices are riskier and subject to more device specific controls, 
these include power wheelchairs and infusion pumps. Class III devices are defined as any device 
in which the guidelines for class I and II are deemed insufficient to demonstrate safety and 
require a pre-market approval, this is the class the CircumBlator
TM
 belongs to. Due to the 
rigorous requirements for class III device approval, device registration may not be required in 
certain European countries (as yearly approval from a Notified Body is considered proof of 
device safety). 
 To gain approval for a class III device the applicant must prepare and submit two 
documents to a Notified Body in order to receive a CE Mark. The first is proof of 
implementation of a Quality Management System (QMS) that complies with ISO 13485 
guidelines. This is the first required step in all regulatory approval processes and in all but two of 
the observed countries are based on ISO 13485 requirements (USA and Brazil have similar 
requirements that predate ISO 13485). The second document is a Design Dossier, an extensive 
technical file that will require a large amount of clinical data. Clinical trials for a CE Mark are 
best conducted in European countries with the strictest interpretations of the CE guidelines such 
as the UK, Germany, France, Sweden, or Switzerland or in partner states that have made large 
efforts to comply with CE guidelines such as Canada and Australia. Clinical trials require 
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approval from a Competent Authority (CA) from the countries they are to be conducted in. 
Competent Authorities are the regulatory bodies of the individual nations within the EFTA and 
have based their regulatory processes around CE guidelines. The size of clinical trials must 
demonstrate proof of safety in man and proof of parity to existing devices at a “statistically 
significant level” (ISO 14155).  What constitutes “statistically significant levels” of data is based 
on precedence and the expected level of risk of the device. For example, a new catheter point 
ablator awarded a CE Mark in 2006 conducted a 210 patient clinical trial (sharps.org) where the 
more novel, less understood Cryoballoon catheter ablator required a 240 patient pivotal trial 
(Medtronic.com). Based on this and other invasive electrophysiological devices approved in the 
last ten years we can expect a clinical trial size for the CircumBlator
TM
 to range between 200 and 
300 patients. 
 With this information in hand, an authorized representative called an EC-Rep located 
within the EU must be appointed and submit the applications to a Notified Body. If the audit is 
successful and the device is approved the Notified Body will then issue a CE Certificate. This 
certificate is valid for one year after which continued approval is subject to yearly audits by a 
Notified Body. Upon being issued a CE Certificate, the manufacturer may produce a Declaration 
of Conformity and begin registering the device in the countries which require registration and 
begin distribution. Registration is frequently not required for class III devices as many nations 
rely on the yearly Notified Body audits to ensure quality. However, even if registration is not 
required, distribution must still comply with all CE directives which include translating all 
labeling into the local language (Bouchez). Post-market surveillance must also be conducted to 
ensure successful yearly audits. 
Regulatory Approval Process in the United States 
 Regulatory approval in the United States is conducted by the FDA. The FDA approval 
process is separate from all other regulatory processes meaning US-based clinical trials will 
always be required regardless of the status of foreign approval. Unique standards must adhered 
to similar to ISO protocols, with random inspections in place of yearly reviews. The only 
international standards followed during the FDA regulatory process are the STED document 
formats. Despite these drawbacks, the United States remains one of the most sought after 
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markets due to its status as the single largest buyer of medical devices in the world. The 
international reputation and acceptance of FDA approval is second only to Europe. 
 The first step in seeking regulatory approval from the FDA is implementing a Quality 
Management System. The FDA’s QMS predates ISO standards and does not recognize ISO 
13485 approval. Instead, the implemented QMS must follow the 21 CFR Part 820 requirements, 
also known as the current Goods Manufacturing Process (fda.gov). As the CircumBlato
rTM
 is a 
substantially novel device, a Pre-IDE trial will likely be required as the device is not 
substantially equivalent to existing market products. This trial is small in scope, with the goal of 
demonstrating safety in man and parity to existing devices. Once IDE approval is granted, 
pivotal trials may start. A pivotal trial conducted in the United States will require 500 to a 1,000 
patients at an expected cost of $5,000,000 to $10,000,000 (gmplabelling.com). Once pivotal trial 
data is collected, a completed PMA application may be submitted. The PMA review will 
theoretically take no longer than 180 days and is contingent on site inspections. 
 The FDA’s regulatory process is regarded as one of the highest standards in the world. 
Part of this is the scope of pivotal trials in the US; the FDA reserves the right to reject devices 
due to new technologies not being “substantial improvements” over existing ones (sharps.org). 
Despite this, the FDA is plagued by bureaucratic issues that impact the approval process, 
including outdated infrastructure and a high turnover rate. Delays are common meaning the 
approval process within the United States can vary between two to five years. 
Table 1 
 
 
Regulatory Approval Process in Japan 
 Much like the FDA, the Japanese approval process is known internationally for its high 
standards. Also, like the FDA, Japanese approval is a long and difficult process that requires 
clinical trials conducted within the country’s boarders regardless of international recognition. 
Recent Device Approvals or Rejections in the US and EU US Trial Size EU Trial Size Status
Sharp's AF catheter ablator 210 N/A Rejected
Distal Protection system for cortorary artery 800 22 Both Approved
Left atrial appendage exclusion for prevention of stroke (in AF patients) 700 250 EU Approved
MACPAF Cryo AF Ablator N/A 108 Rejected
Source: clinicaltrials.gov
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Japan is the fourth largest individual buyer a medical devices worldwide, behind the United 
States, Germany, and France. 
 Regulatory approval in Japan begins with the appointment of a Marketing Authorization 
Holder, called a D-MAH, which will act as a regulatory liaison in the country. Device 
classification must be determined as Japan has a 4 tier classification system where tiers 3 and 4 
do not clearly specify the kinds of devices in each category. Instead, device classification is done 
by an arbitrary approximation of risk of the device. Once this information is known, the D-MAH 
may submit a form for Foreign Manufacturer Accreditation to the PMDA. A quality management 
system must be implemented that complies with ISO 13485 as well as the Ministry of Health, 
Labor, and Welfare Ordinance #169. At this stage, clinical trials must be conducted in Japan. 
Clinical trials in Japan are costly, for high risk devices 400 to 600 Japanese patients may be 
needed (Nagasaka). Combined with the costs of maintaining Japanese personnel, the costs of 
running clinical trials in Japan is comparable to clinical trials in the United States. Once clinical 
data is collected a pre-market approval form may be submitted as well as technical files which 
follow the STED format. Pre-market Approval certificates issued by the PMDA do not expire. 
 Approval in Japan is unfortunately not a quick or easy option for a small company in the 
US. Japan places high importance on the status of home-country approval although it is not 
required. Additionally, the role of the D-MAH is much greater than most regulatory liaisons; 
they possess certain rights in the country related to devices they help approve. Choosing a D-
MAH that is part of an international medical device distributor or consulting firm is 
recommended. 
Cost of Regulatory Approval between the US, EU, and Japan 
 Due to the huge costs associated with clinical trials, the optimal path for approval and 
access to all major markets is best done sequentially rather than concurrently. Outside approval 
only officially benefits the regulatory process in Europe; unfortunately the CE Mark is also the 
quickest and least expensive way to obtain one of the three major approvals. Furthermore, Japan 
places a high value on the status of home-country approval. The order in which approval is 
sought after in these three markets greatly affects access to the worldwide medical device 
market. Obtaining approval in one of these three bodies would normally indicate that you have 
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sufficient clinical data to pursue regulatory approval in almost any other nation in the world 
without the need for additional clinical trials. 
 Due to Japan’s foreign device constraints, smaller market, and comparable regulatory 
costs, it only makes sense to seek Japanese approval following US approval. This makes the 
question of first major market a decision between the EU and the US. Approval in the EU comes 
at an expected cost of $2-3 million and grants access to 30.3% of the medical device market. 
Approval in the US comes at an expected cost of $5-10 million, grants access to 44.4% of the 
medical device taking roughly twice as long to gain approval. With the metric of “cost to access 
1% of the market” it becomes clear that Europe is a much more cost effective first market (US: 
$112,000-224,000 per 1%, EU: $66,000-100,000 per 1%). Combined with other factors, such as 
the acceptance of the CE Mark internationally, aging population of most European nations, and 
lower total capital needed to get to market, Europe becomes the clear best choice. Once 
European approval is granted in the form of a CE Mark, access to all other international markets 
becomes substantially easier, especially in many wealthy smaller nations that make up the list of 
top medical device buyers (Canada, Australia, and South Korea). Consecutively pursuing 
approval in the United States and then Japan is also recommended, as they represent a combined 
54% of medical device purchases worldwide.  
Table 2 
Annual Investment in Medical Devices by 
Country (US Dollars adjusted for inflation)                      
From Selected Market Data 
U.S. 80,130,000,000 
EU Composite 54,760,000,000 
Japan 19,100,000,000 
Canada 2,736,000,000 
South Korea 3,600,000,000 
Australia 1,084,000,000 
Brazil 1,209,000,000 
India 420,000,000 
Russia 1,059,000,000 
China 16,000,000,000 
 
Regulatory Approval outside of the Top Three Markets 
 With clinical data from European trials, the regulatory timetable and cost to access 
markets in multiple other nations drops significantly. These countries regularly accept clinical 
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data from outside their boarders and will likely not require additional studies if the product 
possesses a CE Mark. However, although many nations have streamlined their regulatory 
processes to better match the European model, the regulatory agencies still maintain the final say 
on approval within a specific nation. This section covers the regulatory processes for select 
countries based on their market size. 
Australia 
 The Therapeutic Goods Administration (TGA) is the regulatory body in charge of 
medical device approvals in Australia. The TGA, in an effort to combat medical tourism and 
other failings within its old approval system, redesigned its classification system and regulatory 
process along the guidelines of the Global Harmonization Task Force (GHTF) and European CE 
guidelines. Depending on the scope and requirements of clinical trials, it may be worthwhile to 
pursue Australian and EU approval concurrently, as the TGA is a Notified Body capable of 
issuing a CE Mark (pharmout.com.au). 
 Similar to Europe in its initial steps, the registration process for Australia requires proof 
of compliance with ISO 13485. When submitting a Design Dossier, the European standard 
equivalent may be used. The Australian regulatory process differs from the European system 
during the submission process. Medical Device registration in Australia requires a regulatory 
liaison that resides in the country. Through this liaison, manufacturers evidence (CE Mark) is 
submitted and the device is entered into an electronic registry called the DEAL system. If 
approved, the approval will be posted on the TGA website and a certificate will be issued with 
the device’s registry number. A small fee is required to submit the manufacturer’s evidence and 
list the device online (TGA.gov). 
Brazil 
 Device registration in Brazil begins with the appointment of a Brazilian Registration 
Holder. This must be a company with locations inside Brazil that possess a Company Working 
Allowance permit. Highly novel or high risk devices will require the submission of an Economic 
Information Report assessing the impact the new device could possibly have on the Brazilian 
Market. All electrical devices must obtain INMETRO Certification for electrical safety, although 
this test does not need to be done within Brazil, it is the only nation we observed that had such a 
requirement. Proof of compliance with the Brazilian Goods Manufacturing Practice must also be 
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demonstrated and is subject to inspections every two years (Flood). With these preliminary steps 
completed, the Registration Holder may then submit a technical file to ANVISA for approval. 
Once approved, ANVISA issues a device registration certificate and a letter of authorization, 
both these documents must then be registered at a Brazilian consulate. All certificates issued are 
valid for five years. 
Canada 
 Medical device registration in Canada is handled by Health Canada’s Health Products 
and Food Branch. Like Australia, Canada has tailored their regulatory process to international 
standards and follows the European model whenever possible. First, an ISO13485:2003 
Certificate must be acquired. Approval for an ISO13485:2003 Certificate must be done by a 
CMDCAS accredited registrar. CMDCAS accreditation is managed by Health Canada and many 
European Notified Bodies possess CMDCAS accreditation. The ISO Certificate, Pre-Market 
Review documents, Medical Device License application, and relevant fees must then be sent to 
Health Canada for review and approval. All forms sent in during the approval process must 
follow the international STED format that Canada as adopted (Wisdahl). Once approved the 
device is legal for sale in Canada subject to yearly approval fees. 
 Once the aforementioned steps have been completed, the approved device is totally legal 
for sale in Canada. However, Canada operates under a nationalized healthcare system making the 
Canadian government itself the largest singular buyer of medical devices in the country. Due to 
the country’s huge landmass and relatively small population, using Health Canada as a 
distributor may be the easiest way to disseminate a new product across the country. In order to 
sell directly to the Canadian government, a Private Label Medical Device License must be 
acquired. This is a much faster process than normal device registration and is not subject to 
yearly renewals. Depending on the level of interest, it is possible that Health Canada would 
purchase the rights to manufacture a PLMDL device within the country. 
China 
 China purports a standardized regulatory process in compliance with most EU and US 
guidelines. In practice, approval in China can be substantially more difficult than most nations 
with standardized guidelines. First, a regulatory liaison, called a Legal Agent, and a distributor, 
called an After Sales Agent, must be appointed. Although the Legal and After Sales Agents are 
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involved in the preparation and submission of documents, the device manufacturer is responsible 
for holding all of the necessary forms. A Registration Standard document must be prepared and 
submitted along with a prototype for type testing. Officially, a response for the SFDA should 
take no longer than two to three months but depending on the novelty of the device, it is entirely 
possible that it will be held longer causing an unknown amount of delay in registration (Sun). 
The results of type testing may result in the requirement of additional clinical trials to be held in 
China. If not needed, quality assurance documents may be submitted (ISO13485 Certificate or 
FDA equivalent, CE Mark or FDA Letter of Approval, etc) along with technical files for 
approval. If successful, an Import Medical Device Registration Certificate is issued and is valid 
for four years (Tariah). 
India 
 India’s regulatory body does not classify devices via the tier system used in most of the 
rest of the world. Instead, devices in India are only subject to certain regulatory processes if they 
fall into one of the specific device listings. These listings do not include invasive medical devices 
and are more analogous to class II devices. Instead, regulatory approval relies on the 
appointment of a regulatory liaison and the completion of two forms. The regulatory liaison, 
called the India Authorized Agent, must be an Indian born national with five years’ experience in 
the given field (in this case, an electro-physiologist). The agent must also hold a valid Indian 
wholesale license, called Forms 20B and 21B (Mukherji). Through the agent, a device 
registration form must be submitted called Form 40. This form will require clinical data and 
approval data from the US, EU, Japan, or Australia is sufficient. Once approved the Indian 
governing body (CDSCO) will issue Certificate 41. Upon approval, an import license, called 
Form 10, will also need to be acquired. This import license specifies your in-country distributor 
and is held (along with Certificate 41) by the India Authorized Agent. All forms are valid for 
three years and resubmission of forms is needed for continued approval (CDSCO.gov). 
 India is currently implementing a more complex and more defined regulatory system for 
medical devices. Presently, medical device registration can take place in under a year when 
approached with clinical data already in hand. However, distribution can be difficult outside 
major cities as India is a large, highly diverse, and heavily regional country. Care must be taken 
during the registration process as changing distributors is a difficult process. 
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South Korea 
 Companies without a presence in South Korea must appoint a Korean License holder to 
submit and utilize the necessary certificates for registration in the country. The License Holder in 
Korea is different from many other nations in that it is the device distributors rather than 
manufacturers that must hold the license, and licenses are valid for entire categories of medical 
products, not individual patents. The largest impact of regulatory approval is the designation of 
the distributor before entering the market, as the regulatory process must be repeated to gain 
access to another distributor. While South Korea requires the standard ISO 13485 QMS 
compliance and the submission of a technical file, the standardized SER Technical File may be 
used in this submission. The submission of a technical file will also require the submission of a 
prototype for type testing by the KFDA (ita.doc.gov). Successful completion of these 
submissions will result in a product license issued. Once the product license is obtained the 
Korean License Holder must then apply for a KGMP Certificate. This Certificate is effectively a 
yearly audit on the distributor and proof that they hold both a business license and relevant 
product license. All three of these documents must be presented by the Korean License Holder 
when importing products into the country. 
Russia 
 Regulatory approval in Russia is managed by the Rozsdravnadzor and possesses little 
overlap with other European approvals. Unlike most approval processes which can rely on a 
variety of safety guarantees like quality systems, cite inspection, and post-market surveillance, 
Russian regulatory approval is dependent upon product testing to ensure safety (Ludmila). A 
company must be appointed to act as a regulatory liaison within Russia. Once appointed the 
regulatory liaison seeks out permission to import testing samples into the country. Testing must 
be conducted at authorized expertise centers and hospitals within Russia. Using the data gathered 
in the quality, safety, and efficacy testing, a registration dossier must be compiled and submitted 
to the Rozsdravnadzor. Applicants may be requested to collect additional clinical data or proof of 
home-country approval (although this appears to not be required, the Rozsdravnadzor reserves 
the right to request home-country approval before allowing the device into Russia). If approved, 
a GOST-R Certificate is issued which is valid for one year (Makstrong). 
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Results 
 
Sizing Up Markets and Difficulty of Regulatory Access 
 Comparing the benefit of accessing a particular market against the difficulty of accessing 
that particular market can be difficult. There exists no metric that accurately defines the number 
of arrhythmia patients that we would gain by going into a specific country, so other derivatives 
must be considered. We initially organized ideal countries by those that theoretically had the 
largest number of potential arrhythmia sufferers. This made the countries with the oldest 
populations the most desirable but they all had difficult and involved approval processes (US, 
EU, Japan). As discussed earlier, the costs associated with pursuing approval in these three areas 
at once was not feasible. 
 Instead of following the pathology of arrhythmia, we settled on a more concrete 
measurement, the annual amount spent on medical devices in a given country. This figure 
provided a more accurate look into what we could expect from gaining access to a particular 
country. Once again the US, EU, and Japan were at the top comprising over 75 % of the total 
market, but other nations can more readily be compared against one another. For example 
Australia and Brazil possess similar age spreads and have nearly identical annual expenditures 
on medical devices, but Brazil has nearly five times the population and four times the reported 
instances of arrhythmia when compared to Australia (see Appendix B). This data indicates that a 
countries economic status should have the most influence on whether or not it should be pursued 
as a market. Market size and regulatory ease do not necessarily make a country an ideal location. 
One such example would be India, despite its loose regulatory structure and 1.2 billion 
population, accounts for less than a 0.25% of the worldwide medical device market, making it a 
smaller market than Singapore. In fact, large and highly regionalized countries such as Brazil, 
India, Russia, and China have only recently begun controlling or enforcing medical device 
registration in the past 20 to 30 years. This has hindered their ability to buy devices 
internationally and often indicates that the regulatory system in place is undergoing constant 
changes (Koster). 
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Easy Access 
 Many nations not initially considered or eliminated during the market review may also be 
worth pursuing after acquiring a CE Mark. These small nations often have a high per capita 
income, large annual expenditure on medical devices, and adhere to GHTF or European 
guidelines for clinical data. The timeline for approval in these countries is usually on the order of 
weeks to months, rather than years. Many of these nations rival smaller European nations in 
market size and incur similar registration costs. 
 Singapore possesses a regulatory process that follows GHTF guidelines. Singapore 
device registration requires a regulatory liaison and clinical data. Hong Kong follows a similar 
process, with a registration time of two months. Israel, which was initially eliminated due to 
insufficient market data, grants approval to any existing device with an FDA Letter of Approval 
or CE Mark and is a fairly large buyer of medical devices. Additional nations which rely heavily 
on medical device imports and have relatively simple regulatory processes include Columbia, 
Costa Rica, and the Philippines (emergogroup.com).  
Following International Standards 
 In the present day, the European CE Mark has become the international standard for 
medical device registration throughout most of the world. The CE Mark has gained this status as 
it is the easiest to obtain of the three major standards most often used internationally. This means 
that subsequent regulatory approvals should be sought out in the countries that most recognize 
the CE Mark first. In our analysis, the three countries which most adhere to the European 
guidelines are Australia, Canada, and South Korea in that order. It is highly likely that a device 
as novel as the CircumBlator
TM
 will be required to perform multi-locational clinical trials and we 
recommend attempting to use trial cites in Australia and Canada when seeking a CE Mark if at 
all possible. Gaining access to South Korea is theoretically as easy as gaining access to Canada 
with a CE Mark but language and cultural barriers must be considered as well. Based on this, we 
recommend that approval in Australia, Canada, and South Korea be pursued either concurrently 
with European approval or immediately following CE Certification. Afterward, approval in 
Brazil and India may be worth considering as they represent some of the largest remaining 
markets but pose difficult distribution problems. Based on the need for type testing, distribution 
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issues, and bad international reputations we cannot recommend pursuing regulatory approval in 
the Russian Federation or Peoples Republic of China.  
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Discussion 
 Our initial analysis favoring European CE Marking over alternative major approval 
routes was not surprising. The CE Mark is designed to get products to market safely in as short a 
time as possible and must be loose enough to work within the frameworks of the regulatory 
processes of its 30 member nations. The United States and Japan place a higher importance on 
quality control and (theoretically) safety when compared to the free trade-based approach of the 
CE Mark. Initially, we knew that AblaCor would be pursuing European approval first and the 
reasons became increasingly clear when compared to the other two regional powers. The 
European pathway to initial market access for U.S. medical device startups is the clear best 
choice. 
 Regional influence also appears to play a larger role in international medical device 
markets. There is no international standard, the UN has not attempted to outline one, and the 
Global Harmonization Task Force is not an official body recognized by any government agency. 
The GHTF actually divides their guidelines along geographic regions (Europe, South East Asia, 
and the Americas) which hint that regional hegemonies have a larger influence over the 
regulatory process in a small nation than any notion of an international standard. Certainly this is 
true in many Latin American nations, which are more likely to have a system based on the FDA 
registration process. This could include the actual application process itself, using unique quality 
management standards instead of ISO 13485, or manifest itself in the form of random site 
inspections, reliance on testing, etc. The CE Mark is only applicable to countries lying within the 
EFTA, but many EU member-candidates have adopted guidelines that better follow CE 
directives. Many nations within the CEFTA (Macedonia, Montenegro, and Serbia) may 
effectively be considered countries in which a CE Mark is a sufficient mark of quality to pursue 
registration. South East Asia appears to be the least reliant on any one nation from which 
regulatory processes are based. In fact, many South East Asian nations are turning to the 
European model to more readily gain access to new technologies as they hit the market. South 
Korea leads as having already adopted many CE directives, but a host of smaller nations, 
particularly those where medical tourism is popular, have streamlined registrations that accept 
approvals from most other countries. 
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 While no true international standard exists, countries are increasingly gravitating to a 
more standardized regulatory approach. Most often this results in using the CE Mark as a 
guideline. Countries which did not regulate or enforce medical device guidelines until recently 
are frequently reviewing the registration process and new iterations increasingly resemble an 
existing major standard. India’s new proposed device classifications greatly resemble Europe’s, 
for example, rather than China’s or Japan’s four tier systems. Countries that still possess minor 
testing requirements can often have that testing done through a Notified Body (such as Brazil’s 
INMETRO Certification or South Korea’s type testing). 
Conclusions 
 When comparing regulatory processes to one another, a large number of factors and a 
large number of countries must be considered in order to get an accurate representation. No 
effort to harmonize regulatory standards globally has ever been successful largely because 
national authorities always hold the final say on device approval in any given country. The 
European model for device regulation, while only officially applicable in the EFTA, provides the 
closest thing to an international model for countries which desire access to the newest medical 
technologies immediately. Although nearly half of all clinical trials are conducted in the US, the 
majority are conducted by major US companies, which possess the large amount of capital and 
long-term stability needed to receive an FDA Letter of Approval. The directives of the CE Mark 
emphasize the promotion of trade, by limiting safety concerns to proof of parity and proof of 
safety in man, rather than requiring devices to be substantial improvements over existing ones. 
These factors combined with fewer bureaucratic delays then the FDA approval process makes 
CE Marking the closest thing to an international guideline for device approval. 
 Canada, Australia, and South Korea were chosen as follow ups to CE Marking as they 
most closely follow the directives necessary for European approval. All three accept STED 
documentation, clinical data obtained during CE Marking, and recognize Notified Bodies as 
guaranteers of quality. Their additional requirements are minimal and can be fulfilled through the 
use of a European Notified Body (Canada-specific ISO 13485 certification and Korean type 
testing may both the done through a Notified Body). This makes the realistic costs of entering 
these three countries minimal assuming prior EU approval. The real cost of entering any one of 
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these three markets with a CE Mark in hand is equivalent to regulatory fees, distributor fees 
(through an appointed liaison), and a waiting period less than six months. Canada and Australia 
are ranked slightly ahead of South Korea as they have no type testing requirement and easier 
requirements for a distributor/regulatory liaison. 
 US approval is not initially recommended primarily because of the prohibitive costs and 
time associated with approval. Despite purchasing nearly half of all medical devices and 
conducting nearly half of all clinical trials globally, the United States actually lags three to five 
years behind other developed nations in seeing new medical technologies. Large, established 
medical corporations can afford to pursue US and EU clinical trials concurrently; meaning new 
technologies developed in the US may actually reach European markets first. Even with these 
drawbacks, continued success and mainstream acceptance of the CircumBlator
TM 
will be 
contingent on pursuing FDA approval at some point. Japanese approval faces similar problems; 
but with similar expected cost as US clinical trials, two to three years needed for approval, and 
only a quarter the size of the US market, approval should only be sought in Japan after 
everything else. 
 With this information it makes sense to pursue approval in smaller nations that accept CE 
Marking rather than begin US approval immediately following EU approval. The cost to access 
small but wealthy nations that adhere to some level of CE directives can be as little as thousands 
of dollars. Large emerging economic powers are slightly more difficult to access and at present 
offer a theoretical return equivalent to Australia or Singapore. For this reason it does not make 
sense to pursue approval in India or Brazil until all small wealthy nations have been exhausted. 
India and Brazil have more potential for growth than any of the other observed countries, but due 
to their simplistic and fast regulatory processes, actual approval can be acquired easily at a later 
date when these markets have grown. Other rising economic powers, Russia and China, are not 
recommended for different reasons. Russia relies entirely on device testing, giving their approval 
process a lengthy and expensive step that only accesses a relatively minor market. China is the 
largest single market to be eliminated from consideration for purely regulatory reasons. The 
approval process in China takes an unknown length of time and is fraught with potential IP 
complications. 
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 Overall, access to a majority of markets cannot be done at once. The United States and 
Japan comprise over 50% of all medical device purchases and each requires their own lengthy 
approval process regardless of the status of the device elsewhere. Economic status of a nation is 
the largest indicator of market size, with wealthy nations investing orders of magnitude more on 
medical devices per capita than poorer nations. This makes the path after acquiring a CE Mark 
direct. Approval should be sought in Australia and Canada either concurrently with European 
approval or immediately following it. From there, South Korea is the largest remaining market 
with a CE compliant regulatory process. Large and relatively poor nations pose distribution 
problems but growing markets and economies make India and Brazil good candidates for device 
registration. Small wealthy nations make up a much larger share of the medical device market 
than initially suspected and for this reason we suggest looking into approval in Singapore, Hong 
Kong, and Israel following South Korean approval. Nearly all regulatory processes require some 
kind of post-market surveillance following approval and seeking approval in a country that 
requires additional testing often fulfills this requirement. AblaCor can maintain continued CE 
Mark approval by conducting clinical trials in the United States, Japan, or even Russia and 
submitting this information with the reapplication. 
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Appendix 
 
Glossary of Terms 
 
Competent authority – Any governmental regulatory agency responsible for the registration of 
medical products within that country. Most often refers to device registration in European 
countries after obtaining a CE Mark. 
EFTA – The European Free Trade Association is the area in which CE Mark directives apply. 
Includes the European Union and neighboring Norway, Switzerland, Lichtenstein, and Iceland. 
GHTF – The Global Harmonization Taskforce is a voluntary organization of medical 
professionals that promote am international unified approach to medical product registrations. 
ISO – International organization for Standardization, international guidelines for nation’s 
regulatory processes. ISO 13485 and 14155 are the most commonly adhered to guidelines when 
referring to medical devices. 
ISO 13485:2003 Certification: A widely accepted certificate demonstrating compliance with the 
quality management systems outlined in ISO13485. Accepted in nearly every nation. 
Notified Body – Third party authorized to issue a CE Mark by the EU. May also be qualified to 
carry out other certifications (such as Brazilian INMETRO certification). 
QMS - The organizational structure, procedures, processes and resources needed to ensure 
consistent performance in manufacturing. Proof of sufficient quality management systems is 
required in all regulatory process and is usually fulfilled by ISO standards. 
Regulatory Liaison – A person or company responsible for handling regulatory and sometimes 
distribution of a device in a country you are not based in. Requirements, importance, and legal 
capabilities for a liaison vary greatly by country.  
STED Documentation – Suggested standardized technical file documentation promoted by the 
GHTF. Not universally adopted but frequently accepted in place of technical documentation. 
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Selected Market Data 
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Regulatory Costs and Timetables 
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Historic and Country Specific European Information 
Five Year Rise in Arrhythmia in European Nations 
 
  2007 2008 2009 2010 2011 
Great Britain 7300 12057 14005 14222 15078 
France 18227 22139 26050 28800 31175 
Germany 30202 39500 40000 42000 50000 
Russia 9022 11200 13384 14048 16380 
Ireland 1600 700 800 800 1000 
 
Number of Atrial Fibrillation Ablations and Performing EPs in Europe in 2012 by Country 
 
 
  
Minimum 
Ablating EPs 
# Afib Ablations 
Last Year 
Austria 18 510 
Belgium 38 1898 
Bulgaria 1 3 
Croatia 5 46 
Cyprus 2 3 
Czech rep 20 1590 
Denmark 10 1074 
Estonia 2 115 
Finland 7 476 
France 130 6488 
Germany 200 15000 
Greece 23 340 
Hungary 10 606 
Iceland 1 15 
Ireland 11 450 
Italy 170 
 Latvia 2 69 
Lithuania 3 66 
Luxemburg 1 27 
Malta 1 4 
Netherlands 15 2147 
Norway 4 1147 
Poland 47 1176 
Portugal 18 467 
Romania 14 67 
Slovakia 4 94 
Slovenia 2 118 
Spain 60 1445 
Sweden 10 1428 
Switzerland 21 1595 
United Kingdom 49 4654 
Total 899 43118 
